- Report
- May 2025
- 189 Pages
Global
From €3184EUR$3,545USD£2,719GBP
€3538EUR$3,939USD£3,021GBP
- Report
- May 2025
- 197 Pages
Global
From €3184EUR$3,545USD£2,719GBP
€3538EUR$3,939USD£3,021GBP
- Report
- May 2025
- 190 Pages
Global
From €3184EUR$3,545USD£2,719GBP
€3538EUR$3,939USD£3,021GBP
- Report
- May 2025
- 175 Pages
Global
From €4033EUR$4,490USD£3,444GBP
- Report
- May 2025
- 175 Pages
Global
From €4033EUR$4,490USD£3,444GBP
- Report
- February 2025
- 200 Pages
Global
From €4033EUR$4,490USD£3,444GBP
- Report
- April 2025
- 175 Pages
Global
From €4033EUR$4,490USD£3,444GBP
- Report
- March 2025
- 200 Pages
Global
From €4033EUR$4,490USD£3,444GBP
- Report
- March 2025
- 200 Pages
Global
From €4033EUR$4,490USD£3,444GBP
- Report
- January 2025
- 175 Pages
Global
From €4033EUR$4,490USD£3,444GBP
- Report
- January 2025
- 175 Pages
Global
From €4033EUR$4,490USD£3,444GBP
- Report
- June 2025
- 373 Pages
Global
From €5255EUR$5,850USD£4,487GBP
- Report
- December 2024
- 150 Pages
Global
From €2919EUR$3,250USD£2,493GBP
€4356EUR$4,850USD£3,720GBP
- Report
- August 2024
- 147 Pages
Global
From €2694EUR$2,999USD£2,300GBP
- Report
- May 2025
- 150 Pages
Global
From €2424EUR$2,699USD£2,070GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1123EUR$1,250USD£959GBP
- Clinical Trials
- April 2025
- 50 Pages
Global
From €1347EUR$1,500USD£1,151GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3368EUR$3,750USD£2,876GBP
- Report
- April 2025
- 185 Pages
Global
From €3436EUR$3,825USD£2,934GBP
€4042EUR$4,500USD£3,452GBP
- Report
- June 2025
- 50 Pages
Global
From €2380EUR$2,650USD£2,033GBP

Voriconazole is an antifungal medication used to treat a variety of fungal infections, including those caused by Aspergillus and Candida species. It is a member of the triazole class of antifungal drugs, and is commonly used in the treatment of serious fungal infections in immunocompromised patients. Voriconazole is also used to treat infections caused by other fungi, such as Fusarium and Scedosporium species.
Voriconazole is available in both oral and intravenous formulations, and is generally well tolerated. Common side effects include visual disturbances, rash, and nausea. It is important to note that voriconazole can interact with other medications, and should be used with caution in patients with liver or kidney disease.
Voriconazole is a key player in the infectious diseases drugs market, and is used to treat a variety of fungal infections. It is an important treatment option for immunocompromised patients, and is generally well tolerated.
Some companies in the voriconazole market include Pfizer, Novartis, Merck, and Astellas Pharma. Show Less Read more